Toll‑like receptor 9 agonist stimulation enables osteogenic differentiation without altering the immune status of umbilical cord mesenchymal stem cells

Yang,Yongfeng; Wang,Yanwen; Li,Li; Bao,Ji; Chen,Fei; Zhang,Li

doi:10.3892/mmr.2015.4429

Toll‑like receptor 9 agonist stimulation enables osteogenic differentiation without altering the immune status of umbilical cord mesenchymal stem cells

Authors:
- Yongfeng Yang
- Yanwen Wang
- Li Li
- Ji Bao
- Fei Chen
- Li Zhang
View Affiliations

Affiliations: Laboratory of Pathology, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: October 13, 2015 https://doi.org/10.3892/mmr.2015.4429
Pages: 8077-8084

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) possess three characteristics critical to tissue regeneration; multipotency, low immunogenicity and an undifferentiated status, providing plasticity. However, increasing evidence has indicated that induction of an immune response in vivo can injure and reject MSC‑based tissues. Toll‑like receptors (TLRs) are a family of pathogen‑associated pattern recognition receptors, which are important in bridging the innate and adaptive immune responses. TLRs have been demonstrated to exhibit important MSC biological regulatory functions in previous studies. To confirm the role of TLR9 in the immune status maintenance of MSCs isolated from umbilical cords, the present study performed assessments to detect agonist effects. Following addition of the TLR9 agonist, CpG, to an umbilical cord mesenchymal stem cell (UCMSC) culture medium, a number of methods were used to detect the changes in the biological function of the UCMSCs. Reverse transcription‑quantitative polymerase chain reaction indicated increased levels of pro‑inflammatory molecules and decreased expression levels of stem cell markers following exposure to the TLR9 agonist. However, flow cytometry revealed that activation of TLR9 had no effect on the proliferation of peripheral blood leukocytes or the expression of surface markers. The present study also identified that CpG‑oligodeoxynucleotide promoted MSC osteogenic differentiation, while inhibiting MSC proliferation and migration. These results indicated that TLRs and their ligands may serve as regulators of MSC proliferation and differentiation, and affect the maintenance of MSC multipotency.

View Figures

View References

1	Phinney DG and Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells. 25:2896–2902. 2007. View Article : Google Scholar : PubMed/NCBI
2	Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesen-chymal stem cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
3	Han KH, Ro H, Hong JH, Lee EM, Cho B, Yeom HJ, Kim MG, Oh KH, Ahn C and Yang J: Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl Immunol. 25:7–15. 2011. View Article : Google Scholar : PubMed/NCBI
4	Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, Yamagishi M, Mori H, Kangawa K and Kitamura S: Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angio-genesis and myogenesis. Am J Physiol Heart Circ Physiol. 287:H2670–H2676. 2004. View Article : Google Scholar : PubMed/NCBI
5	Tatebe M, Nakamura R, Kagami H, Okada K and Ueda M: Differentiation of transplanted mesenchymal stem cells in a large osteochondral defect in rabbit. Cytotherapy. 7:520–530. 2005. View Article : Google Scholar : PubMed/NCBI
6	Im GI, Kim DY, Shin JH, Hyun CW and Cho WH: Repair of cartilage defect in the rabbit with cultured mesenchymal stem cells from bone marrow. J Bone Joint Surg Br. 83:289–294. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bensaïd W, Oudina K, Viateau V, Potier E, Bousson V, Blanchat C, Sedel L, Guillemin G and Petite H: De novo reconstruction of functional bone by tissue engineering in the metatarsal sheep model. Tissue Eng. 11:814–824. 2005. View Article : Google Scholar : PubMed/NCBI
8	Harris CT and Cooper LF: Comparison of bone graft matrices for human mesenchymal stem cell-directed osteogenesis. J Biomed Mater Res A. 68:747–755. 2004. View Article : Google Scholar : PubMed/NCBI
9	Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L and Hofmann T: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA. 99:8932–8937. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, et al: Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 104:3581–3587. 2004. View Article : Google Scholar : PubMed/NCBI
11	Van Damme A, Vanden Driessche T, Collen D and Chuah MK: Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther. 2:195–209. 2002. View Article : Google Scholar : PubMed/NCBI
12	Allison M: Genzyme back Osiris, despite Prochymal flop. Nat Biotechnol. 27:966–967. 2009. View Article : Google Scholar : PubMed/NCBI
13	Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD and Li RK: Differentiation of allogeneic mesen-chymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
14	Blasius AL and Beutler B: Intracellular toll-like receptors. Immunity. 32:305–315. 2010. View Article : Google Scholar : PubMed/NCBI
15	Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell. 124:783–801. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lombardo E, DelaRosa O, Mancheño-Corvo P, Menta R, Ramírez C and Büscher D: Toll-like receptor-mediated signaling in human adipose-derived stem cells: Implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A. 15:1579–1589. 2009. View Article : Google Scholar
17	Cassatella MA, Mosna F, Micheletti A, Lisi V, Tamassia N, Cont C, Calzetti F, Pelletier M, Pizzolo G and Krampera M: Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells. 29:1001–1011. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chen W, Liu J, Manuchehrabadi N, Weir MD, Zhu Z and Xu HH: Umbilical cord and bone marrow mesenchymal stem cell seeding on macroporous calcium phosphate for bone regeneration in rat cranial defects. Biomaterials. 34:9917–9925. 2013. View Article : Google Scholar : PubMed/NCBI
19	Fong CY, Chak LL, Biswas A, Tan JH, Gauthaman K, Chan WK and Bongso A: Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev. 7:1–16. 2011. View Article : Google Scholar
20	Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al: Developmental Committee of the European Group for Blood and Marrow Transplantation: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet. 371:1579–1586
21	Shi M, Liu ZW and Wang FS: Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol. 164:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
22	Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR and Zipori D: Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood. 109:1422–1432. 2007. View Article : Google Scholar
23	Shi Y, Su J, Roberts AI, Shou P, Rabson AB and Ren G: How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 33:136–143. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kaplan JM, Youd ME and Lodie TA: Immunomodulatory activity of mesenchymal stem cells. Curr Stem Cell Res Ther. 6:297–316. 2011. View Article : Google Scholar
25	Spaggiari GM, Capobianco A, Becchetti S, Mingari MC and Moretta L: Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 107:1484–1490. 2006. View Article : Google Scholar
26	Li Y and Lin F: Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 120:3436–3443. 2012. View Article : Google Scholar : PubMed/NCBI
27	Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R and Fibbe WE: Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 108:2114–2120. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
29	Torsvik A and Bjerkvig R: Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev. 39:180–188. 2013. View Article : Google Scholar
30	DelaRosa O and Lombardo E: Modulation of adult mesenchymal stem cells activity by toll-like receptors: Implications on therapeutic potential. Mediators Inflamm. 2010:8656012010. View Article : Google Scholar : PubMed/NCBI
31	Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY and Cheng SM: Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One. 8:e726042013. View Article : Google Scholar : PubMed/NCBI